Construction and application evaluation of off-label drug use evaluation system in cancer hospital

LIU Jinglin; WANG Weiping; WANG Hongtao; GAO Ning; ZHANG Chao; ZHOU Xibei; WU Chunnuan; LU Lu; ZHANG Jie; SONG Xiaokun

doi:10.6039/j.issn.1001-0408.2024.17.05

您当前的位置：

首页 >

文章列表页 >

Construction and application evaluation of off-label drug use evaluation system in cancer hospital

更新时间：2024-09-09

- Construction and application evaluation of off-label drug use evaluation system in cancer hospital
- ZHONGGUO YAOFANG Vol. 35, Issue 17, Pages: 2082-2087(2024)
- 作者机构：
  
  1.天津医科大学肿瘤医院药学部，天津　300060
  2.国家恶性肿瘤临床医学研究中心/天津市恶性肿瘤临床医学研究中心/乳腺癌防治教育部重点实验室/天津市肿瘤防治重点实验室，天津　300060
  3.天津医科大学肿瘤医院医务处，天津　300060
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.17.05
  CLC： R95;R979.1
- Published：15 September 2024，
  
  Received：25 January 2024，
  
  Revised：11 August 2024，
- 稿件说明：
移动端阅览
刘婧琳,王伟平,王洪涛等.肿瘤专科医院超说明书用药评价体系的构建与应用评价 ^Δ[J].中国药房,2024,35(17):2082-2087.

LIU Jinglin,WANG Weiping,WANG Hongtao,et al.Construction and application evaluation of off-label drug use evaluation system in cancer hospital[J].ZHONGGUO YAOFANG,2024,35(17):2082-2087.
刘婧琳,王伟平,王洪涛等.肿瘤专科医院超说明书用药评价体系的构建与应用评价 ^Δ[J].中国药房,2024,35(17):2082-2087. DOI： 10.6039/j.issn.1001-0408.2024.17.05.

LIU Jinglin,WANG Weiping,WANG Hongtao,et al.Construction and application evaluation of off-label drug use evaluation system in cancer hospital[J].ZHONGGUO YAOFANG,2024,35(17):2082-2087. DOI： 10.6039/j.issn.1001-0408.2024.17.05.

摘要

目的

为加强肿瘤专科医院超说明书用药的规范化管理提供参考。

方法

构建超说明书用药评价体系，规范我院药品目录外药品超说明书使用的申请、审批、备案流程。比较我院该评价体系构建前（2021年10月1日－2022年9月30日）和构建后（2022年10月1日－2023年9月30日）的超说明书用药申请量、占比、病种类别和药品类型变化；并统计药学部筛选出的具有高级别循证证据支持的用药条目。

结果

我院超说明书用药申请总数量逐步增加，从2021年第4季度的306份增长至2023年第3季度的3 828份。该评价体系构建前1年，共有超说明书用药申请4 482份；该评价体系构建后1年，共有超说明书用药申请11 840份。该评价体系构建后，未备案的超说明书用药比例较上一年度同期显著降低（

＜0.05）。其中，消化系统肿瘤、头颈肿瘤2个病种及放射性药物未再见有未备案的超说明书用药申请；淋巴瘤、乳腺肿瘤和泌尿生殖系统肿瘤3个病种，细胞毒类药物和新型抗肿瘤类药物的未备案超说明书用药申请量降幅均超过70%。我院药学部共筛选出19种药品相关的27条具有高级别循证证据支持的超说明书用药条目，其中25条为超适应证用药。

结论

肿瘤专科医院超说明书用药评价体系的建立有助于临床抗肿瘤药物的合理应用和细化管理。

Abstract

OBJECTIVE

To provide reference for strengthening the standardized management of off-label drug use in cancer hospitals.

METHODS

The evaluation system for off-label drug use was established to standardize the application， approval， and filing process for off-label drug use in our hospital. The changes in off-label drug application quantity， proportion， disease category and drug category in our hospital were compared before （October 1st， 2021-September 30th， 2022） and after （October 1st， 2022-September 30th， 2023） the establishment of the evaluation system； drug items supported by high-level evidence screened by pharmacy department were analyzed statistically.

RESULTS

The number of off-label drug use applications in our hospital had gradually increased， from 306 pieces in the fourth quarter of 2021 to 3 828 pieces in the third quarter of 2023. In the year before the construction of the evaluation system， there were a total of 4 482 applications for off-label drug use， and in the year after the construction of the evaluation system， there were 11 840 applications for off-label drug use. After the construction of the evaluation system， the proportion of unregistered off-label drug use significantly decreased， compared to the same period last year （

＜0.05）. Among them， there were no unregistered applications for off-label drug use for digesti

ve system tumors， head and neck tumors， and radioactive drugs； lymphoma， breast tumors， urogenital system tumors， cytotoxic drugs and new anti-tumor drugs all had a decrease of over 70% in unregistered off-label drug applications. Twenty-seven off-label drug use items related to 19 drugs supported by high-level evidence were screened by the pharmacy department of our hospital， among which 25 items were drug use beyond indication.

CONCLUSIONS

The establishment of off-label drug use evaluation system in cancer hospital is helpful to the rational use and refined management of clinical anti-tumor drugs.

关键词

超说明书用药抗肿瘤药物评价体系循证证据

Keywords

anti-tumor drugsevaluation systemevidence-based reference

references

SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.

ZHANG Y C，WAGNER A K，GUAN X D. Newly approved cancer drugs in China： innovation and clinical benefit[J]. Nat Rev Clin Oncol，2023，20：135-136.

张明悦，张馨，徐彩花，等. 我国超说明书用药的研究现状及热点趋势[J]. 药物流行病学杂志，2024，33（4）：410-421.

ZHANG M Y，ZHANG X，XU C H，et al. Research status and hot trends of off-label drug use in China[J]. Chin J Pharmacoepidemiol，2024，33（4）：410-421.

张镭，谭玲，王少华，等. 国内24家医疗机构超说明书用药现状调查与分析[J]. 中国药学杂志，2016，51（2）：151-154.

ZHANG L，TAN L，WANG S H，et al. Survey on off-label uses of drugs in 24 hospitals[J]. China Pharm J，2016，51（2）：151-154.

徐伟佳，彭崎，黄海渝，等. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒，2024，21（2）：199-203，210.

XU W J，PENG Q，HUANG H Y，et al. Analysis of 285 cases of adverse drug reactions caused by new antitumor drugs[J]. Chin J Pharmacovigil，2024，21（2）：199-203，210.

广东省药学会.超药品说明书用药目录：2023年版新增用法[J]. 今日药学，2023，33（7）：481-498.

Guangdong Pharmaceutical Association. List of off-label drugs：new usage in 2023 edition[J]. Pharma Today，2023，33（7）：481-498.

广东省药学会.《超说明书用药循证评价规范》团体标准：T/GD-PA1-2021[S/OL].[2024-08-09].http：//www.sinopharmacy.com.cn/notification/2310.htmlhttp://www.sinopharmacy.com.cn/notification/2310.html.

Guangdong Pharmaceutical Association. The group standard ofThe Specification of Evidence-based Pharmaceutical Evaluation Method for Off-label Drug Use：T/GD-PA1-2021[S/OL].[2024-08-09]. http：//www.sinopharmacy. com.cn/notification/2310.html．

王珺，侯宁，张文，等. 山东省超药品说明书用药专家共识（2022版）系列：抗肿瘤药物超药品说明书用药专家共识[J]. 中国合理用药探索，2023，20（1）：25-35.

WANG J，HOU N，ZHANG W，et al. Expert consensus on off-label drug use of Shandong Province （2022 edition）：part of antineoplastic drug[J]. Chin J Ration Drug Use，2023，20（1）：25-35.

金瑶，佟志强，董梅，等.东北三省超说明书用药专家共识：实体瘤、血液病篇[J].中国药房，2023，34（23）：2817-2824.

JIN Y，TONG Z Q，DONG M，et al. Expert consensus on off-label drug use in the three Northeastern provinces of China：solid tumors and hematology[J]. China Pharm，2023，34（23）：2817-2824.

邱凯锋，何志超，陈泽鹏，等. 《超说明书用药循证评价规范》团体标准解读[J]. 今日药学，2021，31（11）：811-814.

QIU K F，HE Z C，CHEN Z P，et al. Interpretation on The Specification of Evidence-based Pharmaceutical Evaluation Method for Off-label Drug Use[J]. Pharm Today，2021，31（11）：811-814.

LEE G E，ROSENBERG S M，MAYER E L，et al. Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer[J]. Breast J，2019，25（6）：1104-1110.

ZHANG M C，TIAN S，FU D，et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma：the randomized GUIDANCE-01 trial[J]. Cancer Cell，2023，41（10）：1705-1716.e5.

HOUILLIER C，TAILLANDIER L，DUREAU S，et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger：results of the intergroup ANOCEF-GOELAMS randomized phase Ⅱ PRECIS study[J]. J Clin Oncol，2019，37（10）：823-833.

乐凯迪，刘敏，马颖林，等. 4 800张新型抗肿瘤药物处方专项点评与分析[J]. 中国医院用药评价与分析，2023，9（6）：761-763，768.

LE K D，LIU M，MA Y L，et al. Special review and analysis of 4 800 new antineoplastic prescriptions[J]. Eval Anal Drug Use Hosp China，2023，9（6）：761-763，768.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Correlation analysis between the judgment of medical damage liability disputes related to off-label drug use and evidence-based evidence

Evidence-based medical evidence change of the payment limitation of antitumor drugs in national medical- insurance negotiation

Related Author

BAO Qi

HU Lin

HU Huajie

HUANG Tao

FU Mengyuan

Haishaerjiang·Wushouer

GUAN Xiaodong

SHI Luwen

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰